Cuprina and Aiodine Laboratory Establish Joint Venture to Develop and Market Novel Iodine-Based Solution for New Wound Care Therapy

SINGAPORE, Nov. 18, 2025 — **Cuprina Holdings (Cayman) Limited** (**Nasdaq: CUPR**) (“**Cuprina**” or “**the Company**”), a biomedical firm involved in developing and commercializing products for chronic wounds, infertility, and cosmeceuticals, announced today the signing of a joint venture (JV) agreement with Singapore-based Aiodine Laboratory Pte Ltd. (“Aiodine”). This collaboration aims to develop, test, and bring to market Aiodine’s innovative iodine-based disinfectant solution as a treatment for both chronic and acute wounds, alongside other typical antiseptic uses.

The initial applications planned for this iodine-based solution include an antiseptic wound care formula, disinfectants, and daily household antiseptics. Further potential uses in personal care, oral hygiene, and veterinary applications are currently under consideration. Both companies intend to begin the necessary clinical studies for regulatory approvals across these applications in 2026.

Under the terms of the JV agreement, Cuprina will be responsible for executing global sales strategies, marketing initiatives, and establishing distribution networks for the licensed products. Aiodine Laboratory, conversely, will provide the joint venture with its proprietary iodine technology and specialized technical knowledge.

This iodine-based solution functions by penetrating pathogens and targeting their amino acids, nucleotides, and fatty acids, thereby damaging their structures and leading to their demise or breakdown. A study conducted at the First Affiliated Hospital of Hainan Medical University in Haikou, China, and published in the March 26, 2025, issue of the peer-reviewed *Wounds International*, assessed the solution’s safety and effectiveness in treating four patients with chronic wounds. The research indicated that after two weeks or less of treatment, three of the four patients (one patient having withdrawn from the study) experienced significant wound healing, reduced infection, decreased inflammation, and improved tissue repair, all without exhibiting toxicity or pain. The study concluded that the solution demonstrated potential for greater safety and efficacy compared to existing wound care options.

David Quek, Chief Executive Officer of Cuprina, commented, “Based on the data and findings from this study, combined with the continuous rise in post-COVID hygiene awareness, we believe our novel iodine-based solution holds significant promise not only as a treatment for severe chronic wounds but also for applications as a mouthwash, a topical antiseptic for adults, children, and pets, and potentially in other domains. These prospects enable Cuprina to expand its offerings across the full spectrum of care, delivering solutions that address patient needs from initial intervention through long-term recovery.”

Prof. Patrick Fernandez, PhD, Chief Technology Officer of Aiodine Laboratory, added, “We believe this joint venture with Cuprina creates a robust pathway to potentially deliver our proven, clinically-established iodine science to millions of patients globally.”

Data published by *Fortune Business Insights* indicates that the global wound care market was valued at approximately US$21 billion in 2024, with projections to reach US$36 billion by 2032. Separately, a study by *MarketsandMarkets* estimated the antiseptics and disinfectants market would exceed US$48 million by 2027.

The complete *Wounds International* study can be accessed at:

About Cuprina Holdings (Cayman) Limited

We are a biomedical and biotechnology company based in Singapore, dedicated to the development and commercialization of innovative products for chronic wound management, as well as operating in the health and beauty sectors. Our proficiency in biomedical research allows us to identify and utilize naturally derived materials to develop wound care products, formatted as medical devices that adhere to international standards. For further details, please visit .

About Aiodine Laboratory Pte Ltd.

Aiodine Laboratory is a Singapore-based company specializing in advanced iodine formulations for human health, safety, and hygiene. Its proprietary multi-species iodine technology has demonstrated widespread effectiveness in oral care, wound healing, and antiseptic applications. Learn more at www.aiodine.sg.

FORWARD-LOOKING STATEMENTS

Certain statements within this press release concerning future expectations, plans, and prospects, along with any other statements that are not historical facts, may constitute “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These statements encompass, but are not limited to, those related to anticipated trading commencement and closing dates. The terms “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are employed to identify forward-looking statements, though not all such statements include these identifiers. Actual outcomes may differ substantially from those indicated by these forward-looking statements due to various significant factors, including uncertainties concerning market conditions and the completion of the public offering on the expected terms or at all, as well as other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these and other reasons, investors are advised against placing undue reliance on any forward-looking statements in this press release. Any forward-looking statements contained herein are valid only as of this date, and Cuprina Holdings (Cayman) Limited expressly disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise, except where required by law.

Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email:

Investor Relations Inquiries
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5^th Floor
New York, New York 10036
Office: (646) 893-5835
Email: